Novel drug delivery methods for the treatment of keratitis: moving away from surgical intervention

Garg, Prashant; Venuganti, Venkata Vamsi Krishna; Roy, Aravind; Roy, Girdhari

doi:10.1080/17425247.2019.1690451

Cited by 14 publications

(5 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CLs are explored widely as drug carrier systems to enhance the residence time of the therapeutic molecules on the ocular surface. Various materials have been employed in fabricating CLs without effecting their oxygen permeability and light transmittance ( Dubald et al, 2018 ; Garg et al, 2019 ; Wei et al, 2020 ). One of the major challenges in developing drug delivery systems is to optimize the relevant drug release kinetics to inhibit the microbes ( Hui et al, 2014 ).…”

Section: Ocular Drug Delivery Systems To Treat Keratitismentioning

confidence: 99%

“…These problems are addressed using microneedle ocular patch. Microneedles ocular patch haves an array of 50–1,000 µm sized needles, which are fabricated using ceramic, metals, polymer, and silicon ( Garg et al, 2019 ). The microneedle ocular patches containing amphotericin have also been found to be effective in treating fungal keratitis in rabbits ( Roy et al, 2019 ).…”

Section: Ocular Drug Delivery Systems To Treat Keratitismentioning

confidence: 99%

“…Drug-loaded micelles were nontoxic, and the natamycin released from the micelles suppressed the growth of C. albicans in rabbit models. Nanoparticles are colloidal carrier systems made of natural or synthetic polymers and stores the drug in the polymer shell and deliver them to the target site ( Garg et al, 2019 ). Ahsan et al reported the development of anti-TLR4 antibodies–conjugated gelatin nanoparticles for enhancing the residence time of the drug ketoconazole by anchoring to the cornea.…”

Section: Ocular Drug Delivery Systems To Treat Keratitismentioning

confidence: 99%

See 2 more Smart Citations

Alternative Therapeutic Interventions: Antimicrobial Peptides and Small Molecules to Treat Microbial Keratitis

et al. 2021

View full text Add to dashboard Cite

Microbial keratitis is a leading cause of blindness worldwide and results in unilateral vision loss in an estimated 2 million people per year. Bacteria and fungus are two main etiological agents that cause corneal ulcers. Although antibiotics and antifungals are commonly used to treat corneal infections, a clear trend with increasing resistance to these antimicrobials is emerging at rapid pace. Extensive research has been carried out to determine alternative therapeutic interventions, and antimicrobial peptides (AMPs) are increasingly recognized for their clinical potential in treating infections. Small molecules targeted against virulence factors of the pathogens and natural compounds are also explored to meet the challenges and growing demand for therapeutic agents. Here we review the potential of AMPs, small molecules, and natural compounds as alternative therapeutic interventions for the treatment of corneal infections to combat antimicrobial resistance. Additionally, we have also discussed about the different formats of drug delivery systems for optimal administration of drugs to treat microbial keratitis.

show abstract

Section: Ocular Drug Delivery Systems To Treat Keratitismentioning

confidence: 99%

Section: Ocular Drug Delivery Systems To Treat Keratitismentioning

confidence: 99%

Section: Ocular Drug Delivery Systems To Treat Keratitismentioning

confidence: 99%

See 1 more Smart Citation

Alternative Therapeutic Interventions: Antimicrobial Peptides and Small Molecules to Treat Microbial Keratitis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In recent years, several examples of the mentioned drugs have been incorporated into CLs using many different techniques, and the obtained results have been extensively discussed in previous review papers [21,111,186]. Therapeutic CLs for the treatment of keratitis have also been widely reported in literature reviews [187,188], with promising results for the delivery of biocides [189,190], antifungals [189,[191][192][193][194], and antiviral drugs [195,196].…”

Section: Corneal Diseasesmentioning

confidence: 99%

Therapeutic Ophthalmic Lenses: A Review

2020

View full text Add to dashboard Cite

An increasing incidence of eye diseases has been registered in the last decades in developed countries due to the ageing of population, changes in lifestyle, environmental factors, and the presence of concomitant medical conditions. The increase of public awareness on ocular conditions leads to an early diagnosis and treatment, as well as an increased demand for more effective and minimally invasive solutions for the treatment of both the anterior and posterior segments of the eye. Despite being the most common route of ophthalmic drug administration, eye drops are associated with compliance issues, drug wastage by lacrimation, and low bioavailability due to the ocular barriers. In order to overcome these problems, the design of drug-eluting ophthalmic lenses constitutes a non-invasive and patient-friendly approach for the sustained drug delivery to the eye. Several examples of therapeutic contact lenses and intraocular lenses have been developed, by means of different strategies of drug loading, leading to promising results. This review aims to report the recent advances in the development of therapeutic ophthalmic lenses for the treatment and/or prophylaxis of eye pathologies (i.e., glaucoma, cataract, corneal diseases, or posterior segment diseases) and it gives an overview of the future perspectives and challenges in the field.

show abstract

“…The major dilemma encountered while developing new formulations of ocular drug with poor solubility is low bioavailability. 1 Other factors such as nasolacrimal drainage can necessitate recurrent drug administration. Therefore, lipophilicity, the degree of plasma protein binding and active membrane transport are prerequisites for effective ocular drugs.…”

Section: Introductionmentioning

confidence: 99%

<p>PLGA Nanoparticle Platform for Trans-Ocular Barrier to Enhance Drug Delivery: A Comparative Study Based on the Application of Oligosaccharides in the Outer Membrane of Carriers</p>

Jiang¹,

Jia²,

Qiu³

et al. 2020

IJN

View full text Add to dashboard Cite

The trans-ocular barrier is a key factor limiting the therapeutic efficacy of triamcinolone acetonide. We developed a poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs) surface modified respectively with 2-hydroxypropyl-β-cyclodextrin (2-HP-β-CD), chitosan oligosaccharide and trehalose. Determination of the drug/nanoparticles interactions, characterization of the nanoparticles, in vivo ocular compatibility tests, comparisons of their corneal permeability and their pharmacokinetics in aqueous humor were carried out. Methods: All PLGA NPs were prepared by the single emulsion and evaporation method and the drug-nanoparticle interaction was studied. The physiochemical features and in vitro corneal permeability of NPs were characterized while the aqueous humor pharmacokinetics was performed to evaluate in vivo corneal permeability of NPs. Ocular compatibility of NPs was investigated through Draize and histopathological test. Results: The PLGA NPs with lactide/glycolide ratio of 50:50 and small particle size (molecular weight 10 kDa) achieved optimal drug release and corneal permeability. Surface modification with different oligosaccharides resulted in uniform particle sizes and similar drug-nanoparticle interactions, although 2-HP-β-CD/PLGA NPs showed the highest entrapment efficiency. In vitro evaluation and aqueous humor pharmacokinetics further revealed that 2-HP-β-CD/PLGA NPs had greater trans-ocular permeation and retention compared to chitosan oligosaccharide/PLGA and trehalose/PLGA NPs. No ocular irritation in vivo was detected after applying modified/unmodified PLGA NPs to rabbit's eyes. Conclusion: 2-HP-β-CD/PLGA NPs are a promising nanoplatform for localized ocular drug delivery through topical administration.

show abstract

Novel drug delivery methods for the treatment of keratitis: moving away from surgical intervention

Cited by 14 publications

References 78 publications

Alternative Therapeutic Interventions: Antimicrobial Peptides and Small Molecules to Treat Microbial Keratitis

Alternative Therapeutic Interventions: Antimicrobial Peptides and Small Molecules to Treat Microbial Keratitis

Therapeutic Ophthalmic Lenses: A Review

<p>PLGA Nanoparticle Platform for Trans-Ocular Barrier to Enhance Drug Delivery: A Comparative Study Based on the Application of Oligosaccharides in the Outer Membrane of Carriers</p>

Contact Info

Product

Resources

About